After VT1021 treatments, the mean secreted TSP-1 protein level was significantly upregulated in patients with GBM (7.05 μg/ml); and increased in patients with pancreatic cancer (8.35 μg/ml) and other tumor types (7.55 μg/ml) (Table 3). This evidence concerns the gene THBS1 and glioblastoma.